Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 1;6(4):45. doi: 10.1186/alzrt277

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Kontsekova et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

DC8E8 immunotherapy significantly reduces levels of insoluble tau oligomers in brains of transgenic mice. Tau transgenic mice were immunized with DC8E8 and with an irrelevant antibody, DC51, and brain tissue of the animals was fractionated into soluble and sarcosyl-insoluble tau fractions. (A) and (B) Amount of total soluble tau is unchanged after DC8E8 treatment compared with treatment with a mock antibody, DC51. (C) and (D) Amount of sarcosyl-insoluble tau oligomers in transgenic mouse brain is significantly diminished after treatment with DC8E8 (n = 3, **P < 0.01). All Western blots were stained with pan-tau monoclonal antibody DC25, and lanes 1 to 6 contain samples from individual animals used in the experiments. Signal quantification was performed using AIDA software.